First, the ability of semaglutide to improve glycemic control and reduce body weight contributes to a favorable metabolic environment that reduces inflammation, oxidative stress, and insulin resistancekey drivers of CV and arrhythmic outcomes (42)
The vote counts matter because they show that the recommendations were not unanimous
It hits the same pleasure receptors on cells as many street drugs do
Monitor blood glucose more frequently during episodes of illness
Regulatory agencies, including the FDA and EMA, closely monitor Semaglutide
Current law blocks Medicare weight-loss drug coverage Policy changes expected mid-2026 Medicaid coverage remains state-dependent What This Means for You Check your specific plan: Self-funded employers can still choose to cover Zepbound During open enrollment: Ask HR about 2026 GLP-1 coverage changes Consider alternatives: Wegovy is covered on most Aetna plans with similar efficacy Self-pay options: TrumpRx ($346/month), LillyDirect ($299-$449/month), or Foundayo (~$149/month oral GLP-1)